LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 16

Search options

  1. Article ; Online: Comparative analysis of oral and intravenous iron therapy in rat models of inflammatory anemia and iron deficiency.

    De Souza, Lara Valente / Hoffmann, Alexander / Fischer, Christine / Petzer, Verena / Asshoff, Malte / Theurl, Igor / Tymoszuk, Piotr / Seifert, Markus / Brigo, Natascha / Hilbe, Richard / Demetz, Egon / Von Raffay, Laura / Berger, Sylvia / Barros-Pinkelnig, Marina / Weiss, Guenter

    Haematologica

    2023  Volume 108, Issue 1, Page(s) 135–149

    Abstract: Anemia is a major health issue and associated with increased morbidity. Iron deficiency anemia (IDA) is the most prevalent, followed by anemia of chronic disease (ACD). IDA and ACD often co-exist, challenging diagnosis and treatment. While iron ... ...

    Abstract Anemia is a major health issue and associated with increased morbidity. Iron deficiency anemia (IDA) is the most prevalent, followed by anemia of chronic disease (ACD). IDA and ACD often co-exist, challenging diagnosis and treatment. While iron supplementation is the first-line therapy for IDA, its optimal route of administration and the efficacy of different repletion strategies in ACD are elusive. Female Lewis rats were injected with group A streptococcal peptidoglycan-polysaccharide (PG-APS) to induce inflammatory arthritis with associated ACD and/or repeatedly phlebotomized and fed with a low iron diet to induce IDA, or a combination thereof (ACD/IDA). Iron was either supplemented by daily oral gavage of ferric maltol or by weekly intravenous (i.v.) injection of ferric carboxymaltose for up to 4 weeks. While both strategies reversed IDA, they remained ineffective to improve hemoglobin (Hb) levels in ACD, although oral iron showed slight amelioration of various erythropoiesis-associated parameters. In contrast, both iron treatments significantly increased Hb in ACD/IDA. In ACD and ACD/IDA animals, i.v. iron administration resulted in iron trapping in liver and splenic macrophages, induction of ferritin expression and increased circulating levels of the iron hormone hepcidin and the inflammatory cytokine interleukin-6, while oral iron supplementation reduced interleukin-6 levels. Thus, oral and i.v. iron resulted in divergent effects on systemic and tissue iron homeostasis and inflammation. Our results indicate that both iron supplements improve Hb in ACD/IDA, but are ineffective in ACD with pronounced inflammation, and that under the latter condition, i.v. iron is trapped in macrophages and may enhance inflammation.
    MeSH term(s) Female ; Animals ; Rats ; Interleukin-6 ; Rats, Inbred Lew ; Anemia/diagnosis ; Iron/metabolism ; Anemia, Iron-Deficiency/drug therapy ; Anemia, Iron-Deficiency/etiology ; Anemia, Iron-Deficiency/diagnosis ; Inflammation/drug therapy
    Chemical Substances Interleukin-6 ; perferryl iron (14127-54-9) ; Iron (E1UOL152H7)
    Language English
    Publishing date 2023-01-01
    Publishing country Italy
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2022.281149
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Persistent somatic symptoms are key to individual illness perception at one year after COVID-19 in a cross-sectional analysis of a prospective cohort study.

    Hüfner, Katharina / Tymoszuk, Piotr / Sahanic, Sabina / Luger, Anna / Boehm, Anna / Pizzini, Alex / Schwabl, Christoph / Koppelstätter, Sabine / Kurz, Katharina / Asshoff, Malte / Mosheimer-Feistritzer, Birgit / Pfeifer, Bernhard / Rass, Verena / Schroll, Andrea / Iglseder, Sarah / Egger, Alexander / Wöll, Ewald / Weiss, Günter / Helbok, Raimund /
    Widmann, Gerlig / Sonnweber, Thomas / Tancevski, Ivan / Sperner-Unterweger, Barbara / Löffler-Ragg, Judith

    Journal of psychosomatic research

    2023  Volume 169, Page(s) 111234

    Abstract: Objective: Subjective illness perception (IP) can differ from physician's clinical assessment results. Herein, we explored patient's IP during coronavirus disease 2019 (COVID-19) recovery.: Methods: Participants of the prospective observation CovILD ... ...

    Abstract Objective: Subjective illness perception (IP) can differ from physician's clinical assessment results. Herein, we explored patient's IP during coronavirus disease 2019 (COVID-19) recovery.
    Methods: Participants of the prospective observation CovILD study (ClinicalTrials.gov: NCT04416100) with persistent somatic symptoms or cardiopulmonary findings one year after COVID-19 were analyzed (n = 74). Explanatory variables included demographic and comorbidity, COVID-19 course and one-year follow-up data of persistent somatic symptoms, physical performance, lung function testing, chest computed tomography and trans-thoracic echocardiography. Factors affecting IP (Brief Illness Perception Questionnaire) one year after COVID-19 were identified by regularized modeling and unsupervised clustering.
    Results: In modeling, 33% of overall IP variance (R
    Conclusion: Persistent somatic symptoms rather than abnormalities in cardiopulmonary testing influence IP one year after COVID-19. Modifying IP represents a promising innovative approach to treatment of post-COVID-19 condition. Besides COVID-19 severity, individual IP should guide rehabilitation and psychological therapy decisions.
    MeSH term(s) Humans ; COVID-19 ; Prospective Studies ; Cross-Sectional Studies ; Medically Unexplained Symptoms ; Perception ; Fatigue/etiology
    Language English
    Publishing date 2023-03-17
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80166-5
    ISSN 1879-1360 ; 0022-3999
    ISSN (online) 1879-1360
    ISSN 0022-3999
    DOI 10.1016/j.jpsychores.2023.111234
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: COVID-19 and its continuing burden after 12 months: a longitudinal observational prospective multicentre trial.

    Sahanic, Sabina / Tymoszuk, Piotr / Luger, Anna K / Hüfner, Katharina / Boehm, Anna / Pizzini, Alex / Schwabl, Christoph / Koppelstätter, Sabine / Kurz, Katharina / Asshoff, Malte / Mosheimer-Feistritzer, Birgit / Coen, Maximilian / Pfeifer, Bernhard / Rass, Verena / Egger, Alexander / Hörmann, Gregor / Sperner-Unterweger, Barbara / Helbok, Raimund / Wöll, Ewald /
    Weiss, Günter / Widmann, Gerlig / Tancevski, Ivan / Sonnweber, Thomas / Löffler-Ragg, Judith

    ERJ open research

    2023  Volume 9, Issue 2

    Abstract: Background: Recovery trajectories from coronavirus disease 2019 (COVID-19) call for longitudinal investigation. We aimed to characterise the kinetics and status of clinical, cardiopulmonary and mental health recovery up to 1 year following COVID-19.: ... ...

    Abstract Background: Recovery trajectories from coronavirus disease 2019 (COVID-19) call for longitudinal investigation. We aimed to characterise the kinetics and status of clinical, cardiopulmonary and mental health recovery up to 1 year following COVID-19.
    Methods: Clinical evaluation, lung function testing (LFT), chest computed tomography (CT) and transthoracic echocardiography were conducted at 2, 3, 6 and 12 months after disease onset. Submaximal exercise capacity, mental health status and quality of life were assessed at 12 months. Recovery kinetics and patterns were investigated by mixed-effect logistic modelling, correlation and clustering analyses. Risk of persistent symptoms and cardiopulmonary abnormalities at the 1-year follow-up were modelled by logistic regression.
    Findings: Out of 145 CovILD study participants, 108 (74.5%) completed the 1-year follow-up (median age 56.5 years; 59.3% male; 24% intensive care unit patients). Comorbidities were present in 75% (n=81). Key outcome measures plateaued after 180 days. At 12 months, persistent symptoms were found in 65% of participants; 33% suffered from LFT impairment; 51% showed CT abnormalities; and 63% had low-grade diastolic dysfunction. Main risk factors for cardiopulmonary impairment included pro-inflammatory and immunological biomarkers at early visits. In addition, we deciphered three recovery clusters separating almost complete recovery from patients with post-acute inflammatory profile and an enrichment in cardiopulmonary residuals from a female-dominated post-COVID-19 syndrome with reduced mental health status.
    Conclusion: 1 year after COVID-19, the burden of persistent symptoms, impaired lung function, radiological abnormalities remains high in our study population. Yet, three recovery trajectories are emerging, ranging from almost complete recovery to post-COVID-19 syndrome with impaired mental health.
    Language English
    Publishing date 2023-03-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 2827830-6
    ISSN 2312-0541
    ISSN 2312-0541
    DOI 10.1183/23120541.00317-2022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Mitochondrial Respiration in Response to Iron Deficiency Anemia: Comparison of Peripheral Blood Mononuclear Cells and Liver.

    Fischer, Christine / Valente de Souza, Lara / Komlódi, Timea / Garcia-Souza, Luiz F / Volani, Chiara / Tymoszuk, Piotr / Demetz, Egon / Seifert, Markus / Auer, Kristina / Hilbe, Richard / Brigo, Natascha / Petzer, Verena / Asshoff, Malte / Gnaiger, Erich / Weiss, Günter

    Metabolites

    2022  Volume 12, Issue 3

    Abstract: Iron is an essential component for metabolic processes, including oxygen transport within hemoglobin, tricarboxylic acid (TCA) cycle activity, and mitochondrial energy transformation. Iron deficiency can thus lead to metabolic dysfunction and eventually ... ...

    Abstract Iron is an essential component for metabolic processes, including oxygen transport within hemoglobin, tricarboxylic acid (TCA) cycle activity, and mitochondrial energy transformation. Iron deficiency can thus lead to metabolic dysfunction and eventually result in iron deficiency anemia (IDA), which affects approximately 1.5 billion people worldwide. Using a rat model of IDA induced by phlebotomy, we studied the effects of IDA on mitochondrial respiration in peripheral blood mononuclear cells (PBMCs) and the liver. Furthermore, we evaluated whether the mitochondrial function evaluated by high-resolution respirometry in PBMCs reflects corresponding alterations in the liver. Surprisingly, mitochondrial respiratory capacity was increased in PBMCs from rats with IDA compared to the controls. In contrast, mitochondrial respiration remained unaffected in livers from IDA rats. Of note, citrate synthase activity indicated an increased mitochondrial density in PBMCs, whereas it remained unchanged in the liver, partly explaining the different responses of mitochondrial respiration in PBMCs and the liver. Taken together, these results indicate that mitochondrial function determined in PBMCs cannot serve as a valid surrogate for respiration in the liver. Metabolic adaptions to iron deficiency resulted in different metabolic reprogramming in the blood cells and liver tissue.
    Language English
    Publishing date 2022-03-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662251-8
    ISSN 2218-1989
    ISSN 2218-1989
    DOI 10.3390/metabo12030270
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: COVID-19 and its continuing burden after 12 months

    Sabina Sahanic / Piotr Tymoszuk / Anna K. Luger / Katharina Hüfner / Anna Boehm / Alex Pizzini / Christoph Schwabl / Sabine Koppelstätter / Katharina Kurz / Malte Asshoff / Birgit Mosheimer-Feistritzer / Maximilian Coen / Bernhard Pfeifer / Verena Rass / Alexander Egger / Gregor Hörmann / Barbara Sperner-Unterweger / Raimund Helbok / Ewald Wöll /
    Günter Weiss / Gerlig Widmann / Ivan Tancevski / Thomas Sonnweber / Judith Löffler-Ragg

    ERJ Open Research, Vol 9, Iss

    a longitudinal observational prospective multicentre trial

    2023  Volume 2

    Abstract: Background Recovery trajectories from coronavirus disease 2019 (COVID-19) call for longitudinal investigation. We aimed to characterise the kinetics and status of clinical, cardiopulmonary and mental health recovery up to 1 year following COVID-19. ... ...

    Abstract Background Recovery trajectories from coronavirus disease 2019 (COVID-19) call for longitudinal investigation. We aimed to characterise the kinetics and status of clinical, cardiopulmonary and mental health recovery up to 1 year following COVID-19. Methods Clinical evaluation, lung function testing (LFT), chest computed tomography (CT) and transthoracic echocardiography were conducted at 2, 3, 6 and 12 months after disease onset. Submaximal exercise capacity, mental health status and quality of life were assessed at 12 months. Recovery kinetics and patterns were investigated by mixed-effect logistic modelling, correlation and clustering analyses. Risk of persistent symptoms and cardiopulmonary abnormalities at the 1-year follow-up were modelled by logistic regression. Findings Out of 145 CovILD study participants, 108 (74.5%) completed the 1-year follow-up (median age 56.5 years; 59.3% male; 24% intensive care unit patients). Comorbidities were present in 75% (n=81). Key outcome measures plateaued after 180 days. At 12 months, persistent symptoms were found in 65% of participants; 33% suffered from LFT impairment; 51% showed CT abnormalities; and 63% had low-grade diastolic dysfunction. Main risk factors for cardiopulmonary impairment included pro-inflammatory and immunological biomarkers at early visits. In addition, we deciphered three recovery clusters separating almost complete recovery from patients with post-acute inflammatory profile and an enrichment in cardiopulmonary residuals from a female-dominated post-COVID-19 syndrome with reduced mental health status. Conclusion 1 year after COVID-19, the burden of persistent symptoms, impaired lung function, radiological abnormalities remains high in our study population. Yet, three recovery trajectories are emerging, ranging from almost complete recovery to post-COVID-19 syndrome with impaired mental health.
    Keywords Medicine ; R
    Subject code 150 ; 610
    Language English
    Publishing date 2023-03-01T00:00:00Z
    Publisher European Respiratory Society
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.

    Nairz, Manfred / Haschka, David / Dichtl, Stefanie / Sonnweber, Thomas / Schroll, Andrea / Aßhoff, Malte / Mindur, John E / Moser, Patrizia L / Wolf, Dominik / Swirski, Filip K / Theurl, Igor / Cerami, Anthony / Brines, Michael / Weiss, Günter

    Scientific reports

    2017  Volume 7, Issue 1, Page(s) 13012

    Abstract: Two distinct forms of the erythropoietin receptor (EPOR) mediate the cellular responses to erythropoietin (EPO) in different tissues. EPOR homodimers signal to promote the maturation of erythroid progenitor cells. In other cell types, including immune ... ...

    Abstract Two distinct forms of the erythropoietin receptor (EPOR) mediate the cellular responses to erythropoietin (EPO) in different tissues. EPOR homodimers signal to promote the maturation of erythroid progenitor cells. In other cell types, including immune cells, EPOR and the ß-common receptor (CD131) form heteromers (the innate repair receptor; IRR), and exert tissue protective effects. We used dextran sulphate sodium (DSS) to induce colitis in C57BL/6 N mice. Once colitis was established, mice were treated with solvent, EPO or the selective IRR agonist cibinetide. We found that both cibinetide and EPO ameliorated the clinical course of experimental colitis in mice, resulting in improved weight gain and survival. Correspondingly, DSS-exposed mice treated with cibinetide or EPO displayed preserved tissue integrity due to reduced infiltration of myeloid cells and diminished production of pro-inflammatory disease mediators including cytokines, chemokines and nitric oxide synthase-2. Experiments using LPS-activated primary macrophages revealed that the anti-inflammatory effects of cibinetide were dependent on CD131 and JAK2 functionality and were mediated via inhibition of NF-κB subunit p65 activity. Cibinetide activation of the IRR exerts potent anti-inflammatory effects, especially within the myeloid population, reduces disease activity and mortality in mice. Cibinetide thus holds promise as novel disease-modifying therapeutic of inflammatory bowel disease.
    MeSH term(s) Animals ; Chemokines/metabolism ; Colitis/chemically induced ; Colitis/drug therapy ; Colitis/immunology ; Colitis/pathology ; Cytokine Receptor Common beta Subunit/metabolism ; Dextran Sulfate ; Disease Progression ; Erythropoietin/pharmacology ; Female ; Humans ; Immunity, Innate/drug effects ; Intestinal Mucosa/drug effects ; Intestinal Mucosa/pathology ; Janus Kinase 2/metabolism ; Macrophages/drug effects ; Macrophages/metabolism ; Male ; Mice, Inbred C57BL ; Myeloid Cells/drug effects ; Myeloid Cells/metabolism ; Oligopeptides/pharmacology ; Oligopeptides/therapeutic use ; Phosphatidylinositol 3-Kinases/metabolism ; Phosphorylation/drug effects ; Receptors, Erythropoietin/metabolism ; Solubility ; T-Lymphocytes, Helper-Inducer/drug effects ; T-Lymphocytes, Helper-Inducer/metabolism ; Transcription Factor RelA/metabolism
    Chemical Substances Chemokines ; Cytokine Receptor Common beta Subunit ; Oligopeptides ; Receptors, Erythropoietin ; Transcription Factor RelA ; innate repair receptor ; Erythropoietin (11096-26-7) ; Dextran Sulfate (9042-14-2) ; cibinetide (9W5677JKDA) ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; Janus Kinase 2 (EC 2.7.10.2)
    Language English
    Publishing date 2017-10-12
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-017-13046-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis

    Manfred Nairz / David Haschka / Stefanie Dichtl / Thomas Sonnweber / Andrea Schroll / Malte Aßhoff / John E. Mindur / Patrizia L. Moser / Dominik Wolf / Filip K. Swirski / Igor Theurl / Anthony Cerami / Michael Brines / Günter Weiss

    Scientific Reports, Vol 7, Iss 1, Pp 1-

    2017  Volume 12

    Abstract: Abstract Two distinct forms of the erythropoietin receptor (EPOR) mediate the cellular responses to erythropoietin (EPO) in different tissues. EPOR homodimers signal to promote the maturation of erythroid progenitor cells. In other cell types, including ... ...

    Abstract Abstract Two distinct forms of the erythropoietin receptor (EPOR) mediate the cellular responses to erythropoietin (EPO) in different tissues. EPOR homodimers signal to promote the maturation of erythroid progenitor cells. In other cell types, including immune cells, EPOR and the ß-common receptor (CD131) form heteromers (the innate repair receptor; IRR), and exert tissue protective effects. We used dextran sulphate sodium (DSS) to induce colitis in C57BL/6 N mice. Once colitis was established, mice were treated with solvent, EPO or the selective IRR agonist cibinetide. We found that both cibinetide and EPO ameliorated the clinical course of experimental colitis in mice, resulting in improved weight gain and survival. Correspondingly, DSS-exposed mice treated with cibinetide or EPO displayed preserved tissue integrity due to reduced infiltration of myeloid cells and diminished production of pro-inflammatory disease mediators including cytokines, chemokines and nitric oxide synthase-2. Experiments using LPS-activated primary macrophages revealed that the anti-inflammatory effects of cibinetide were dependent on CD131 and JAK2 functionality and were mediated via inhibition of NF-κB subunit p65 activity. Cibinetide activation of the IRR exerts potent anti-inflammatory effects, especially within the myeloid population, reduces disease activity and mortality in mice. Cibinetide thus holds promise as novel disease-modifying therapeutic of inflammatory bowel disease.
    Keywords Medicine ; R ; Science ; Q
    Subject code 616
    Language English
    Publishing date 2017-10-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: Persistent somatic symptoms are key to individual illness perception at one year after COVID-19

    Hüfner, Katharina / Tymoszuk, Piotr / Sahanic, Sabina / Luger, Anna / Boehm, Anna / Pizzini, Alex / Schwabl, Christoph / Koppelstätter, Sabine / Kurz, Katharina / Asshoff, Malte / Mosheimer-Feistritzer, Birgit / Pfeifer, Bernhard / Rass, Verena / Schroll, Andrea / Iglseder, Sarah / Egger, Alexander / Wöll, Ewald / Weiss, Günter / Helbok, Raimund /
    Widmann, Gerlig / Sonnweber, Thomas / Tancevski, Ivan / Sperner-Unterweger, Barbara / Löffler-Ragg, Judith

    medRxiv

    Abstract: Background: Sequelae of Coronavirus disease 2019 (COVID-19) were investigated by both patient-initiated and academic initiatives. Patient9s subjective illness perceptions might differ from physician9s clinical assessment results. Herein, we explored ... ...

    Abstract Background: Sequelae of Coronavirus disease 2019 (COVID-19) were investigated by both patient-initiated and academic initiatives. Patient9s subjective illness perceptions might differ from physician9s clinical assessment results. Herein, we explored factors influencing patient9s perception during COVID-19 recovery. Methods: Participants of the prospective observation CovILD study with persistent somatic symptoms or cardiopulmonary findings at the clinical follow-up one year after COVID-19 were analyzed (n = 74). Explanatory variables included baseline demographic and comorbidity data, COVID-19 course and one-year follow-up data of persistent somatic symptoms, physical performance, lung function testing (LFT), chest computed tomography (CT) and trans-thoracic echocardiography (TTE). Factors affecting illness perception (Brief Illness Perception Questionnaire, BIPQ) were identified by penalized multi-parameter regression and unsupervised clustering. Results: In modeling, 47% of overall illness perception variance at one year after COVID-19 was attributed to fatigue intensity, reduced physical performance, hair loss and baseline respiratory comorbidity. Overall illness perception was independent of LFT results, pulmonary lesions in CT or heart abnormality in TTE. As identified by clustering, persistent somatic symptom count, fatigue, diminished physical performance, dyspnea, hair loss and sleep problems at the one-year follow-up and severe acute COVID-19 were associated with the BIPQ domains of concern, emotional representation, complaints, disease timeline and consequences. Conclusion: Persistent somatic symptoms rather than clinical assessment results, revealing lung and heart abnormalities, impact on severity and quality of illness perception at one year after COVID-19 and may foster unhelpful coping mechanisms. Besides COVID-19 severity, individual illness perception should be taken into account when allocating rehabilitation and psychological therapy resources. Study registration: ClinicalTrials.gov: NCT04416100.
    Keywords covid19
    Language English
    Publishing date 2022-09-06
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2022.09.05.22279602
    Database COVID19

    Kategorien

  9. Article ; Online: Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial.

    Sonnweber, Thomas / Sahanic, Sabina / Pizzini, Alex / Luger, Anna / Schwabl, Christoph / Sonnweber, Bettina / Kurz, Katharina / Koppelstätter, Sabine / Haschka, David / Petzer, Verena / Boehm, Anna / Aichner, Magdalena / Tymoszuk, Piotr / Lener, Daniela / Theurl, Markus / Lorsbach-Köhler, Almut / Tancevski, Amra / Schapfl, Anna / Schaber, Marc /
    Hilbe, Richard / Nairz, Manfred / Puchner, Bernhard / Hüttenberger, Doris / Tschurtschenthaler, Christoph / Aßhoff, Malte / Peer, Andreas / Hartig, Frank / Bellmann, Romuald / Joannidis, Michael / Gollmann-Tepeköylü, Can / Holfeld, Johannes / Feuchtner, Gudrun / Egger, Alexander / Hoermann, Gregor / Schroll, Andrea / Fritsche, Gernot / Wildner, Sophie / Bellmann-Weiler, Rosa / Kirchmair, Rudolf / Helbok, Raimund / Prosch, Helmut / Rieder, Dietmar / Trajanoski, Zlatko / Kronenberg, Florian / Wöll, Ewald / Weiss, Günter / Widmann, Gerlig / Löffler-Ragg, Judith / Tancevski, Ivan

    The European respiratory journal

    2021  Volume 57, Issue 4

    Abstract: Background: After the 2002/2003 severe acute respiratory syndrome outbreak, 30% of survivors exhibited persisting structural pulmonary abnormalities. The long-term pulmonary sequelae of coronavirus disease 2019 (COVID-19) are yet unknown, and ... ...

    Abstract Background: After the 2002/2003 severe acute respiratory syndrome outbreak, 30% of survivors exhibited persisting structural pulmonary abnormalities. The long-term pulmonary sequelae of coronavirus disease 2019 (COVID-19) are yet unknown, and comprehensive clinical follow-up data are lacking.
    Methods: In this prospective, multicentre, observational study, we systematically evaluated the cardiopulmonary damage in subjects recovering from COVID-19 at 60 and 100 days after confirmed diagnosis. We conducted a detailed questionnaire, clinical examination, laboratory testing, lung function analysis, echocardiography and thoracic low-dose computed tomography (CT).
    Results: Data from 145 COVID-19 patients were evaluated, and 41% of all subjects exhibited persistent symptoms 100 days after COVID-19 onset, with dyspnoea being most frequent (36%). Accordingly, patients still displayed an impaired lung function, with a reduced diffusing capacity in 21% of the cohort being the most prominent finding. Cardiac impairment, including a reduced left ventricular function or signs of pulmonary hypertension, was only present in a minority of subjects. CT scans unveiled persisting lung pathologies in 63% of patients, mainly consisting of bilateral ground-glass opacities and/or reticulation in the lower lung lobes, without radiological signs of pulmonary fibrosis. Sequential follow-up evaluations at 60 and 100 days after COVID-19 onset demonstrated a vast improvement of symptoms and CT abnormalities over time.
    Conclusion: A relevant percentage of post-COVID-19 patients presented with persisting symptoms and lung function impairment along with radiological pulmonary abnormalities >100 days after the diagnosis of COVID-19. However, our results indicate a significant improvement in symptoms and cardiopulmonary status over time.
    MeSH term(s) COVID-19 ; Humans ; Lung/diagnostic imaging ; Prospective Studies ; Pulmonary Fibrosis ; SARS-CoV-2
    Language English
    Publishing date 2021-04-29
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.03481-2020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.

    Asshoff, Malte / Petzer, Verena / Warr, Matthew R / Haschka, David / Tymoszuk, Piotr / Demetz, Egon / Seifert, Markus / Posch, Wilfried / Nairz, Manfred / Maciejewski, Pat / Fowles, Peter / Burns, Christopher J / Smith, Gregg / Wagner, Kay-Uwe / Weiss, Guenter / Whitney, J Andrew / Theurl, Igor

    Blood

    2017  Volume 129, Issue 13, Page(s) 1823–1830

    Abstract: Patients with myelofibrosis (MF) often develop anemia and frequently become dependent on red blood cell transfusions. Results from a phase 2 study for the treatment of MF with the Janus kinase 1/2 (JAK1/2) inhibitor momelotinib (MMB) demonstrated that ... ...

    Abstract Patients with myelofibrosis (MF) often develop anemia and frequently become dependent on red blood cell transfusions. Results from a phase 2 study for the treatment of MF with the Janus kinase 1/2 (JAK1/2) inhibitor momelotinib (MMB) demonstrated that MMB treatment ameliorated anemia, which was unexpected for a JAK1/2 inhibitor, because erythropoietin-mediated JAK2 signaling is essential for erythropoiesis. Using a rat model of anemia of chronic disease, we demonstrated that MMB treatment can normalize hemoglobin and red blood cell numbers. We found that this positive effect is driven by direct inhibition of the bone morphogenic protein receptor kinase activin A receptor, type I (ACVR1), and the subsequent reduction of hepatocyte hepcidin production. Of note, ruxolitinib, a JAK1/2 inhibitor approved for the treatment of MF, had no inhibitory activity on this pathway. Further, we demonstrated the effect of MMB is not mediated by direct inhibition of JAK2-mediated ferroportin (FPN1) degradation, because neither MMB treatment nor myeloid-specific deletion of JAK2 affected FPN1 expression. Our data support the hypothesis that the improvement of inflammatory anemia by MMB results from inhibition of ACVR1-mediated hepcidin expression in the liver, which leads to increased mobilization of sequestered iron from cellular stores and subsequent stimulation of erythropoiesis.
    MeSH term(s) Activin Receptors, Type I/antagonists & inhibitors ; Anemia/drug therapy ; Animals ; Benzamides/pharmacology ; Benzamides/therapeutic use ; Bone Morphogenetic Protein Receptors, Type I/antagonists & inhibitors ; Chronic Disease ; Hepatocytes/metabolism ; Hepcidins/biosynthesis ; Iron/metabolism ; Primary Myelofibrosis/complications ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use ; Rats
    Chemical Substances Benzamides ; Hepcidins ; Pyrimidines ; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (6O01GMS00P) ; Iron (E1UOL152H7) ; Activin Receptors, Type I (EC 2.7.11.30) ; Acvr1 protein, rat (EC 2.7.11.30) ; Bone Morphogenetic Protein Receptors, Type I (EC 2.7.11.30)
    Language English
    Publishing date 2017-02-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2016-09-740092
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top